PTPN22 and systemic lupus erythematosus: In contrast, the rs33996649 SNP in which arginine is substituted with a glutamine residue at position 263 within the catalytic domain (R263Q variant) decreases the phosphatase activity [30] of PTPN22 and reduces the risk of developing SLE [30], RA [32], and UC [34].